½ÃÀ庸°í¼­
»óǰÄÚµå
1542512

¼¼°èÀÇ ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global Recombinant Proteins Manufacturing Services Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 189 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â Á¶»ç ±â°£ÀÎ 2024-2032³âÀÇ CAGR 11.89%·Î, 2023³â 27¾ï 6,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â ¾à 76¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º´Â »ý¸í°øÇÐ ¹× ¼öŹÁ¦Á¶±â°ü(CMO)ÀÌ ´Ù¾çÇÑ ¸ñÀûÀ¸·Î ÀçÁ¶ÇÕ ´Ü¹éÁúÀ» »ý»êÇϱâ À§ÇØ Á¦°øÇÏ´Â °øÁ¤ ¹× ½Ã¼³À» ¸»ÇÕ´Ï´Ù. ÀçÁ¶ÇÕ ´Ü¹éÁúÀº ÀϹÝÀûÀ¸·Î ¹ÚÅ׸®¾Æ, È¿¸ð, Æ÷À¯·ù ¼¼Æ÷ ¶Ç´Â ½Ä¹°°ú °°Àº »ý¹°Ã¼¸¦ À¯Àü°øÇÐÀûÀ¸·Î Á¶ÀÛÇÏ¿© ¿øÇϴ ƯÁ¤ ´Ü¹éÁúÀ» ¹ßÇöÇϵµ·Ï Á¶ÀÛÇÏ¿© »ý»êµË´Ï´Ù. ÀÌ·¯ÇÑ ´Ü¹éÁúÀº Á¦¾à, »ý¸í°øÇÐ, ¿¬±¸, Áø´Ü, »ê¾÷ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º ½ÃÀåÀº ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÀÇÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ´ÜŬ·Ð Ç×ü ¹× ¹é½Å°ú °°Àº »ý¹°Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä·Î ÀÎÇÑ ¹ÙÀÌ¿À Á¦¾à »ê¾÷ÀÇ ¼ºÀåÀÌ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. »ý¹°Á¦Á¦´Â ´Ù¾çÇÑ Áúº´À» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖÀ¸¸ç, À̸¦ À§ÇØ ÀçÁ¶ÇÕ ´Ü¹éÁúÀÇ »ý»êÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. »ý¸í°úÇÐ ¹× »ý¸í°øÇÐ ¿¬±¸°³¹ß Ȱµ¿, À¯Àü°øÇÐÀÇ ¹ßÀü, ¼öŹÁ¦Á¶ÀÇ ¾Æ¿ô¼Ò½Ì Ãß¼¼´Â ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, COVID-19·Î ÀÎÇØ °­Á¶µÈ ÆÒµ¥¹Í ´ëºñÀÇ Çʿ伺, ´Ü¹éÁú ¹ßÇö ¹× Á¤Á¦ ±â¼úÀÇ Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÈ÷ ¹ÙÀÌ¿ÀÀǾàǰ ºÎ¹®¿¡¼­ ½Å·ÚÇÒ ¼ö ÀÖ°í ±ÔÁ¤À» ÁؼöÇÏ´Â Á¦Á¶ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÅÈï ½ÃÀå°ú ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ Á¦°øÇÏ´Â ¸ÂÃãÇü ¿É¼Çµµ ÇѸòÀ» Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº »ê¾÷ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº ¼¼°è ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º ½ÃÀåÀÇ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡°¡ ÇâÈÄ ±âȸ¿Í ÇÔ²² °¢ Á¦Ç° ¶Ç´Â ¼­ºñ½ºÀÇ ´ë»ó °èÃþÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

Á¦Ç° ¹× ¼­ºñ½º ¹üÀ§º°

  • Á¦Ç°(»çÀÌÅäÄ«ÀÎ-¼ºÀåÀÎÀÚ(ÀÎÅÍÆä·Ð(IFN), ÀÎÅÍ·ùŲ(IL), ±âŸ), Ç×ü, ¸é¿ª°ü¹®´Ü¹éÁú, ¹ÙÀÌ·¯½º Ç׿ø, È¿¼Ò(Ű³ª¾ÆÁ¦, ´ë»çÈ¿¼Ò, ±âŸ), ÀçÁ¶ÇÕ Á¶Àý´Ü¹éÁú, È£¸£¸ó, ±âŸ)
  • »ý»ê ¼­ºñ½º

Àû¿ë ¹üÀ§º°

  • ½Å¾à ¹× ÀǾàǰ °³¹ß
  • Ä¡·áÁ¦(»ý¹°Á¦Á¦, ¹é½Å, ¼¼Æ÷-À¯ÀüÀÚÄ¡·áÁ¦, ±âŸ)
  • Á¶»ç
  • ±âŸ

ÃÖÁ¾»ç¿ëÀÚº°

  • Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷
  • ÇÐ°è ¹× ¿¬±¸±â°ü
  • Áø´Ü¿¬±¸¼Ò
  • ±âŸ

¼÷ÁÖ¼¼Æ÷ÀÇ ¹üÀ§º°

  • Æ÷À¯·ù ½Ã½ºÅÛ
  • °ïÃæ ¼¼Æ÷
  • È¿¸ð ¹× °õÆÎÀÌ
  • ¹ÚÅ׸®¾Æ ¼¼Æ÷
  • ±âŸ

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼­´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

Ä¿½ºÅÒ ¿ä°ÇÀÌ ÀÖ´Â °æ¿ì, ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. ´ç»çÀÇ Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °³¿ä

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ½º³À¼ô

Á¦3Àå ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º - »ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • ´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º ½ÃÀå ºÐ¼® : Á¦Ç°¡¤¼­ºñ½º ¹üÀ§º°

  • °³¿ä Á¦Ç°¡¤¼­ºñ½º ¹üÀ§º°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Á¦Ç°¡¤¼­ºñ½º ¹üÀ§º° ºÐ¼®
  • Á¦Ç°(»çÀÌÅäÄ«ÀΡ¤¼ºÀåÀÎÀÚ(ÀÎÅÍÆä·Ð(IFN), ÀÎÅÍ·ùŲ(IL), ±âŸ), Ç×ü, ¸é¿ª üũÆ÷ÀÎÆ® ´Ü¹éÁú, ¹ÙÀÌ·¯½º Ç׿ø, È¿¼Ò(Ű³ª¾ÆÁ¦, ´ë»ç È¿¼Ò, ±âŸ), ÀçÁ¶ÇÕ Á¦¾î ´Ü¹éÁú, È£¸£¸ó, ±âŸ)
  • »ý»ê ¼­ºñ½º

Á¦6Àå ¼¼°èÀÇ ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º ½ÃÀå ºÐ¼® : Àû¿ë ¹üÀ§º°

  • °³¿ä Àû¿ë ¹üÀ§º°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Àû¿ë ¹üÀ§º° ºÐ¼®
  • Drug Discovery¡¤ÀǾàǰ °³¹ß
  • Ä¡·áÁ¦(»ý¹°Á¦Á¦, ¹é½Å, ¼¼Æ÷¡¤À¯ÀüÀÚ Ä¡·á, ±âŸ)
  • ¿¬±¸
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚ ¹üÀ§º°

  • °³¿ä ÃÖÁ¾»ç¿ëÀÚ ¹üÀ§º°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ÃÖÁ¾»ç¿ëÀÚ ¹üÀ§º° ºÐ¼®
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Çмú¡¤¿¬±¸±â°ü
  • Áø´Ü ¿¬±¸¼Ò
  • ±âŸ

Á¦8Àå ÀçÁ¶ÇÕ ´Ü¹éÁú ¼¼°è ½ÃÀå ºÐ¼® : ¼÷ÁÖ¼¼Æ÷ ¹üÀ§º°

  • °³¿ä ¼÷ÁÖ¼¼Æ÷ ¹üÀ§º°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ¼÷ÁÖ¼¼Æ÷ ¹üÀ§º° ºÐ¼®
  • Æ÷À¯·ù°è
  • °ïÃæ ¼¼Æ÷
  • È¿¸ð¡¤Áø±Õ
  • ¼¼±Õ ¼¼Æ÷
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹Ì ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ ºÎ¹®º°
    • À¯·´ ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ±¹°¡º° ¸®½ºÆ®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ÀçÁ¶ÇÕ ´Ü¹éÁú Á¦Á¶ ¼­ºñ½º ±â¾÷ÀÇ °æÀï ±¸µµ

  • ÀçÁ¶ÇÕ ´Ü¹éÁú ½ÃÀåÀÇ °æÀï
  • Á¦ÈÞ¡¤Çù·Â¡¤ÇÕÀÇ
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° Ãâ½Ã
  • ±âŸ °³¹ß

Á¦11Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Abcam Plc
  • Sino Biological Inc.
  • R&D Systems Inc.
  • GenScript
  • Bio-Rad Laboratories Inc.
  • Merck KGaA
  • Thermo Fisher Scientific
  • Proteintech Group Inc.
  • Enzo Life Sciences Inc.
  • Abnova Corp.
  • RayBiotech Life Inc.
  • Stemcell Technologies Inc
KSA 24.09.19

The global demand for Recombinant Proteins Manufacturing Services Market is presumed to reach the market size of nearly USD 7.6 Billion by 2032 from USD 2.76 Billion in 2023 with a CAGR of 11.89% under the study period 2024-2032.

Recombinant protein manufacturing services refer to the processes and facilities offered by biotechnology and contract manufacturing organizations (CMOs) to produce recombinant proteins for various purposes. Recombinant proteins are produced by genetically engineering organisms, typically bacteria, yeast, mammalian cells, or even plants, to express specific proteins of interest. These proteins are used in various fields, including pharmaceuticals, biotechnology, research, diagnostics, and industrial applications.

MARKET DYNAMICS

The recombinant proteins manufacturing services market is experiencing growth due to several key factors. The expansion of the biopharmaceutical industry, driven by the demand for biologic drugs like monoclonal antibodies and vaccines, is a primary driver. Biologic drugs are increasingly used in treating various diseases, necessitating the production of recombinant proteins, which these services provide. Research and development activities in life sciences and biotechnology, advancements in genetic engineering, and the outsourcing trend in contract manufacturing further boost demand. The rising prevalence of chronic diseases, the imperative for pandemic preparedness highlighted by COVID-19, and ongoing technological advancements in protein expression and purification techniques contribute to the market's growth. Regulatory approvals, especially in the biopharmaceutical sector, ensure the demand for reliable and compliant manufacturing services. Emerging markets and the customization options service providers offer also play a role.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Recombinant Proteins Manufacturing Services. The growth and trends of Recombinant Proteins Manufacturing Services industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Recombinant Proteins Manufacturing Services market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product & Services Scope

  • Product (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILs), Others), Antibodies, Immune Checkpoint Proteins, Virus Antigens, Enzymes (Kinases, Metabolic Enzymes, Others), Recombinant Regulatory Protein, Hormones, Others)
  • Production Services

By Application Scope

  • Drug Discovery & Development
  • Therapeutics (Biologics, Vaccines, Cell & Gene Therapies, Others)
  • Research
  • Others

By End-user Scope

  • Pharma & Biotechnology Companies
  • Academic & Research Institutes
  • Diagnostic Laboratories
  • Others

By Host Cell Scope

  • Mammalian Systems
  • Insect Cells
  • Yeast & Fungi
  • Bacterial Cells
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Recombinant Proteins Manufacturing Services market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Recombinant Proteins Manufacturing Services market include Abcam Plc, Sino Biological Inc., R&D Systems Inc., GenScript, Bio-Rad Laboratories Inc., Merck KGaA, Thermo Fisher Scientific, Proteintech Group Inc., Enzo Life Sciences Inc., Abnova Corp., RayBiotech Life Inc., Stemcell Technologies Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. RECOMBINANT PROTEINS MANUFACTURING SERVICES - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product & Services Scope
    • 3.7.2 Market Attractiveness Analysis By Application Scope
    • 3.7.3 Market Attractiveness Analysis By End-user Scope
    • 3.7.4 Market Attractiveness Analysis By Host Cell Scope
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET ANALYSIS BY PRODUCT & SERVICES SCOPE

  • 5.1. Overview By Product & Services Scope
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Product & Services Scope
  • 5.4. Product (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILs), Others), Antibodies, Immune Checkpoint Proteins, Virus Antigens, Enzymes (Kinases, Metabolic Enzymes, Others), Recombinant Regulatory Protein, Hormones, Others) Historic and Forecast Sales By Regions
  • 5.5. Production Services Historic and Forecast Sales By Regions

6. GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET ANALYSIS BY APPLICATION SCOPE

  • 6.1. Overview By Application Scope
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Application Scope
  • 6.4. Drug Discovery & Development Historic and Forecast Sales By Regions
  • 6.5. Therapeutics (Biologics, Vaccines, Cell & Gene Therapies, Others) Historic and Forecast Sales By Regions
  • 6.6. Research Historic and Forecast Sales By Regions
  • 6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET ANALYSIS BY END-USER SCOPE

  • 7.1. Overview By End-user Scope
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By End-user Scope
  • 7.4. Pharma & Biotechnology Companies Historic and Forecast Sales By Regions
  • 7.5. Academic & Research Institutes Historic and Forecast Sales By Regions
  • 7.6. Diagnostic Laboratories Historic and Forecast Sales By Regions
  • 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL RECOMBINANT PROTEIN MARKET ANALYSIS BY HOST CELL SCOPE

  • 8.1. Overview By Host Cell Scope
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Host Cell Scope
  • 8.4. Mammalian Systems Historic and Forecast Sales By Regions
  • 8.5. Insect Cells Historic and Forecast Sales By Regions
  • 8.6. Yeast & Fungi Historic and Forecast Sales By Regions
  • 8.7. Bacterial Cells Historic and Forecast Sales By Regions
  • 8.8. Others Historic and Forecast Sales By Regions

9. GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE RECOMBINANT PROTEINS MANUFACTURING SERVICES COMPANIES

  • 10.1. Recombinant Protein Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF RECOMBINANT PROTEINS MANUFACTURING SERVICES INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Abcam Plc
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Sino Biological Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. R&D Systems Inc.
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. GenScript
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Bio-Rad Laboratories Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Merck KGaA
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Thermo Fisher Scientific
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Proteintech Group Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Enzo Life Sciences Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Abnova Corp.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. RayBiotech Life Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Stemcell Technologies Inc
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦